Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of doses of broad-spectrum beta-lactams and vancomycin in septic chronic hemodialysis patients
2011-001573-10Phase 4Completed
- Sponsor
- Erasmus Hospital
- Start
- Oct 2011
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin, ceftazidime and meropenem in sepsis, Bacteremia, fungemia and 1 more (3 arms), sponsored by Erasmus Hospital. Primary endpoint: Pharmacokinetic parameters of ceftazidime, meropenem, and vancomycin. Started Oct 2011; status: completed.
02
Drugs
vancomycinceftazidimemeropenem
03
Conditions
sepsisBacteremiafungemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2011-001573-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001573-10.